Allogene Therapeutics has discontinued the fludarabine, cyclophosphamide, and ALLO-647 (FCA) arm of its pivotal ALPHA3 study in first-line large B-cell lymphomaB-cell lymphoma (LBCL). This follows a Grade 5 adverse event (hepatic failure believed to be caused by disseminated adenovirus infection) attributed to ALLO-647, an anti-CD52 monoclonal antibody. The study now proceeds with a two-arm design comparing cemacabtagene ansegedleucel (cema-cel) after standard FC lymphodepletion to the current observation standard of care. An early review of safety and biomarker data from the FC and cema-cel arms indicated an encouraging minimal residual disease (MRD) conversion rate and a favorable safety profile.
This decision reflects a strategic recalibration of Allogene’s approach to allogeneic CAR T-cell therapy. Abandoning the augmented lymphodepletion strategy using ALLO-647 simplifies trial execution and potentially streamlines regulatory review for cema-cel. This shift also marks an important turn away from multi-agent conditioning regimens toward more operationally feasible approaches using standard FC. The move aligns with growing industry recognition that intensified lymphodepletion, while potentially enhancing CAR T-cell engraftment, also carries significant safety risks, particularly regarding viral reactivation and infections.
This change has far-reaching implications. For Allogene, it clarifies the development path for cema-cel by reducing complexity and focusing on standard FC lymphodepletion. This simplification could lead to faster trial enrollment, expedited regulatory timelines, and potentially wider adoption in community settings. The company is also moving away from ALLO-647 across its pipeline, focusing instead on its Dagger platform technology, designed to minimize or eliminate the need for traditional lymphodepletion strategies. This underscores a broader industry trend towards minimizing pre-conditioning intensity to improve the safety and accessibility of CAR T-cell therapies.
For the broader allogeneic CAR T-cell field, this event reinforces the ongoing debate about the optimal lymphodepletion strategy. It highlights the delicate balance between maximizing efficacy through enhanced engraftment and managing toxicity risks associated with more intensive pre-conditioning. Competitors pursuing augmented lymphodepletion strategies will likely face heightened scrutiny regarding safety monitoring and risk mitigation.
Looking ahead, the scheduled futility analysis for ALPHA3, comparing MRD conversion rates, remains on track for the first half of 2026. However, the removal of the FCA arm will undoubtedly affect data interpretation and potentially impact statistical power calculations. Allogene now needs to demonstrate convincingly that cema-cel with standard FC lymphodepletion provides sufficient clinical benefit to warrant approval. Further monitoring of long-term safety data and the durability of response will be critical. The long-term success of this strategic pivot will depend on the robustness of the clinical data generated with standard FC and market acceptance of an approach that emphasizes a balance of efficacy and safety in the first-line LBCL setting. Ultimately, this incident highlights the challenges in balancing clinical promise with operational realities in the allogeneic CAR T-cell therapy space.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
Innovation in Clinical Trials: From Microbiome Therapies to Platform Consolidation
1 year ago[…] have required complex and often harsh pre-conditioning protocols. By streamlining this step, Allogene’s approach reduces patient burden while maintaining efficacy, making CAR-T more scalable and accessible to […]